Kurs
-1,31%
Likviditet
1,79 MSEK
Kalender
| Est. tid* | ||
| 2026-08-14 | 08:00 | Kvartalsrapport 2026-Q2 |
| 2026-03-31 | N/A | X-dag ordinarie utdelning NXTMS 0.00 SEK |
| 2026-03-30 | N/A | Årsstämma |
| 2026-02-26 | - | Bokslutskommuniké 2025 |
| 2025-08-15 | - | Kvartalsrapport 2025-Q2 |
| 2025-03-28 | - | X-dag ordinarie utdelning NXTMS 0.00 SEK |
| 2025-03-27 | - | Årsstämma |
| 2025-02-27 | - | Bokslutskommuniké 2024 |
| 2024-08-16 | - | Kvartalsrapport 2024-Q2 |
| 2024-04-02 | - | X-dag ordinarie utdelning NXTMS 0.00 SEK |
| 2024-03-28 | - | Årsstämma |
| 2024-02-27 | - | Bokslutskommuniké 2023 |
| 2023-08-18 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-05 | - | X-dag ordinarie utdelning NXTMS 0.00 SEK |
| 2023-03-31 | - | Årsstämma |
| 2023-02-27 | - | Bokslutskommuniké 2022 |
| 2022-08-12 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-09 | - | X-dag ordinarie utdelning NXTMS 0.00 SEK |
| 2022-03-31 | - | Årsstämma |
| 2022-02-28 | - | Bokslutskommuniké 2021 |
| 2021-08-13 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-17 | - | Split NXTMS 100:1 |
| 2021-04-30 | - | X-dag ordinarie utdelning NXTMS 0.00 SEK |
| 2021-04-29 | - | Årsstämma |
| 2021-03-01 | - | Extra Bolagsstämma 2021 |
| 2021-02-26 | - | Bokslutskommuniké 2020 |
| 2020-08-14 | - | Kvartalsrapport 2020-Q2 |
| 2020-04-01 | - | X-dag ordinarie utdelning NXTMS 0.00 SEK |
| 2020-02-28 | - | Bokslutskommuniké 2019 |
| 2019-11-11 | - | Extra Bolagsstämma 2019 |
| 2019-08-16 | - | Kvartalsrapport 2019-Q2 |
| 2019-03-28 | - | X-dag ordinarie utdelning NXTMS 0.00 SEK |
| 2019-03-25 | - | Årsstämma |
| 2019-03-04 | - | Bokslutskommuniké 2018 |
| 2018-11-26 | - | Split NXTMS 30:1 |
| 2018-11-21 | - | Extra Bolagsstämma 2018 |
| 2018-08-16 | - | Kvartalsrapport 2018-Q2 |
| 2018-03-29 | - | X-dag ordinarie utdelning NXTMS 0.00 SEK |
| 2018-03-28 | - | Årsstämma |
| 2018-02-28 | - | Bokslutskommuniké 2017 |
| 2017-08-16 | - | Kvartalsrapport 2017-Q2 |
| 2017-03-29 | - | X-dag ordinarie utdelning NXTMS 0.00 SEK |
| 2017-03-28 | - | Årsstämma |
| 2017-02-28 | - | Bokslutskommuniké 2016 |
| 2017-02-17 | - | Extra Bolagsstämma 2017 |
| 2016-08-17 | - | Kvartalsrapport 2016-Q2 |
| 2016-03-31 | - | Årsstämma |
| 2016-02-29 | - | Bokslutskommuniké 2015 |
| 2015-12-22 | - | Extra Bolagsstämma 2015 |
| 2015-08-20 | - | Kvartalsrapport 2015-Q2 |
| 2015-03-31 | - | Årsstämma |
| 2015-02-26 | - | Bokslutskommuniké 2014 |
Beskrivning
| Land | Finland |
|---|---|
| Lista | First North Finland |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Company announcement, Helsinki, 5 March 2026 at 12 PM (EET)
Nexstim Plc Publishes 2025 Annual Report
Nexstim Plc ("Nexstim" or "Company") announces the publication of its 2025 Annual Report. The annual report is available in English and Finnish under the "Investors" section of the Company's website at nexstim.com/investors/financial-reports-and-presentations.
The Annual Report includes the Report of the Board of Directors, Parent Company and Consolidated Financial Statements as well as the Auditor's Report. A copy of the Annual Report is attached to this announcement.
NEXSTIM PLC
Mikko Karvinen, CEO
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
The Company’s Certified Adviser is DNB Carnegie Investment Bank AB.
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the NBS System 6, which is the only FDA-cleared and CE-marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA-cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE-marked for the treatment of major depression, chronic neuropathic pain as well as post-operative rehabilitation of motor deficits of the upper limb.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit www.nexstim.com